Loading…
Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Saved in:
| Published in: | Antimicrobial Agents and Chemotherapy 1992-05, Vol.36 (5), p.1062-1067 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-a471t-8a41d95cd4034be97cbe59b6f02ff58a36f49f248285da59ec394623bcc99ee33 |
|---|---|
| cites | |
| container_end_page | 1067 |
| container_issue | 5 |
| container_start_page | 1062 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 36 |
| creator | RAMPHAL, R BOLGER, M OBLON, D. J SHERERTZ, R. J MALONE, J. D RAND, K. H GILLIOM, M SHANDS, J. W KRAMER, B. S |
| description | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
| doi_str_mv | 10.1128/AAC.36.5.1062 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73151138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73151138</sourcerecordid><originalsourceid>FETCH-LOGICAL-a471t-8a41d95cd4034be97cbe59b6f02ff58a36f49f248285da59ec394623bcc99ee33</originalsourceid><addsrcrecordid>eNp1kU-LFDEQxRtR1nH16FGIIB6EHpNOJ5MseBgG_8GCF_Ua0unKTJbupE3SI7OfyI9pxhnW9eApCe9XVan3quo5wUtCGvF2vd4sKV-yJcG8eVAtCJai5kzyh9UCY87rVuD2cfUkpRtc3kzii-qCMIKpbBfVr-_amzAejPPIJeRDRtojSAl8dnpARZuCLw8ULMo7QM67PwKMk4vOoBxB5_EIRNi6ckE2RGShi24A5GHOMUzgCznp7AqXCmjA7Z3fIgM261vXl7orpFHUvg-ju4UeTTGkCUx2e0Apz_3hafXI6iHBs_N5WX378P7r5lN9_eXj5836utbtiuRa6Jb0kpm-xbTtQK5MB0x23OLGWiY05baVtmlFI1ivmQRTbOAN7YyREoDSy-rdqe80dyP0pvw46kFN0Y06HlTQTv2reLdT27BXRAhBeal_fa6P4ccMKavRJQPDoD2EOakVLd4TKgpYn0BTVk0R7N0MgtUxWVWSVZQrpo7JFv7NiddpbNRNmKMvPvwXfnF_i7-tT7kX_dVZ18nowRbnjUt3GKO0IStWsJcnbOe2u58ugirDldbm3qjfEbTJxA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73151138</pqid></control><display><type>article</type><title>Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study</title><source>American Society for Microbiology</source><source>Open Access: PubMed Central</source><creator>RAMPHAL, R ; BOLGER, M ; OBLON, D. J ; SHERERTZ, R. J ; MALONE, J. D ; RAND, K. H ; GILLIOM, M ; SHANDS, J. W ; KRAMER, B. S</creator><creatorcontrib>RAMPHAL, R ; BOLGER, M ; OBLON, D. J ; SHERERTZ, R. J ; MALONE, J. D ; RAND, K. H ; GILLIOM, M ; SHANDS, J. W ; KRAMER, B. S</creatorcontrib><description>Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.36.5.1062</identifier><identifier>PMID: 1510394</identifier><identifier>CODEN: AACHAX</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Adolescent ; Adult ; Aged ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteria - isolation & purification ; Biological and medical sciences ; Ceftazidime ; Ceftazidime - administration & dosage ; Ceftazidime - therapeutic use ; Drug Therapy, Combination - therapeutic use ; Female ; Fever - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Neutropenia ; Neutropenia - drug therapy ; Neutropenia - microbiology ; Pharmacology. Drug treatments ; Prospective Studies ; Random Allocation ; Research Article ; Superinfection - prevention & control ; Vancomycin ; Vancomycin - administration & dosage ; Vancomycin - therapeutic use</subject><ispartof>Antimicrobial Agents and Chemotherapy, 1992-05, Vol.36 (5), p.1062-1067</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a471t-8a41d95cd4034be97cbe59b6f02ff58a36f49f248285da59ec394623bcc99ee33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.36.5.1062$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.36.5.1062$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3188,3189,27924,27925,52751,52752,52753,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5332175$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1510394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RAMPHAL, R</creatorcontrib><creatorcontrib>BOLGER, M</creatorcontrib><creatorcontrib>OBLON, D. J</creatorcontrib><creatorcontrib>SHERERTZ, R. J</creatorcontrib><creatorcontrib>MALONE, J. D</creatorcontrib><creatorcontrib>RAND, K. H</creatorcontrib><creatorcontrib>GILLIOM, M</creatorcontrib><creatorcontrib>SHANDS, J. W</creatorcontrib><creatorcontrib>KRAMER, B. S</creatorcontrib><title>Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study</title><title>Antimicrobial Agents and Chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><description>Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteria - isolation & purification</subject><subject>Biological and medical sciences</subject><subject>Ceftazidime</subject><subject>Ceftazidime - administration & dosage</subject><subject>Ceftazidime - therapeutic use</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Female</subject><subject>Fever - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neutropenia</subject><subject>Neutropenia - drug therapy</subject><subject>Neutropenia - microbiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Research Article</subject><subject>Superinfection - prevention & control</subject><subject>Vancomycin</subject><subject>Vancomycin - administration & dosage</subject><subject>Vancomycin - therapeutic use</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNp1kU-LFDEQxRtR1nH16FGIIB6EHpNOJ5MseBgG_8GCF_Ua0unKTJbupE3SI7OfyI9pxhnW9eApCe9XVan3quo5wUtCGvF2vd4sKV-yJcG8eVAtCJai5kzyh9UCY87rVuD2cfUkpRtc3kzii-qCMIKpbBfVr-_amzAejPPIJeRDRtojSAl8dnpARZuCLw8ULMo7QM67PwKMk4vOoBxB5_EIRNi6ckE2RGShi24A5GHOMUzgCznp7AqXCmjA7Z3fIgM261vXl7orpFHUvg-ju4UeTTGkCUx2e0Apz_3hafXI6iHBs_N5WX378P7r5lN9_eXj5836utbtiuRa6Jb0kpm-xbTtQK5MB0x23OLGWiY05baVtmlFI1ivmQRTbOAN7YyREoDSy-rdqe80dyP0pvw46kFN0Y06HlTQTv2reLdT27BXRAhBeal_fa6P4ccMKavRJQPDoD2EOakVLd4TKgpYn0BTVk0R7N0MgtUxWVWSVZQrpo7JFv7NiddpbNRNmKMvPvwXfnF_i7-tT7kX_dVZ18nowRbnjUt3GKO0IStWsJcnbOe2u58ugirDldbm3qjfEbTJxA</recordid><startdate>19920501</startdate><enddate>19920501</enddate><creator>RAMPHAL, R</creator><creator>BOLGER, M</creator><creator>OBLON, D. J</creator><creator>SHERERTZ, R. J</creator><creator>MALONE, J. D</creator><creator>RAND, K. H</creator><creator>GILLIOM, M</creator><creator>SHANDS, J. W</creator><creator>KRAMER, B. S</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19920501</creationdate><title>Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study</title><author>RAMPHAL, R ; BOLGER, M ; OBLON, D. J ; SHERERTZ, R. J ; MALONE, J. D ; RAND, K. H ; GILLIOM, M ; SHANDS, J. W ; KRAMER, B. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a471t-8a41d95cd4034be97cbe59b6f02ff58a36f49f248285da59ec394623bcc99ee33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteria - isolation & purification</topic><topic>Biological and medical sciences</topic><topic>Ceftazidime</topic><topic>Ceftazidime - administration & dosage</topic><topic>Ceftazidime - therapeutic use</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Female</topic><topic>Fever - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neutropenia</topic><topic>Neutropenia - drug therapy</topic><topic>Neutropenia - microbiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Research Article</topic><topic>Superinfection - prevention & control</topic><topic>Vancomycin</topic><topic>Vancomycin - administration & dosage</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RAMPHAL, R</creatorcontrib><creatorcontrib>BOLGER, M</creatorcontrib><creatorcontrib>OBLON, D. J</creatorcontrib><creatorcontrib>SHERERTZ, R. J</creatorcontrib><creatorcontrib>MALONE, J. D</creatorcontrib><creatorcontrib>RAND, K. H</creatorcontrib><creatorcontrib>GILLIOM, M</creatorcontrib><creatorcontrib>SHANDS, J. W</creatorcontrib><creatorcontrib>KRAMER, B. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial Agents and Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RAMPHAL, R</au><au>BOLGER, M</au><au>OBLON, D. J</au><au>SHERERTZ, R. J</au><au>MALONE, J. D</au><au>RAND, K. H</au><au>GILLIOM, M</au><au>SHANDS, J. W</au><au>KRAMER, B. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study</atitle><jtitle>Antimicrobial Agents and Chemotherapy</jtitle><addtitle>Antimicrob Agents Chemother</addtitle><date>1992-05-01</date><risdate>1992</risdate><volume>36</volume><issue>5</issue><spage>1062</spage><epage>1067</epage><pages>1062-1067</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><coden>AACHAX</coden><abstract>Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>1510394</pmid><doi>10.1128/AAC.36.5.1062</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial Agents and Chemotherapy, 1992-05, Vol.36 (5), p.1062-1067 |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73151138 |
| source | American Society for Microbiology; Open Access: PubMed Central |
| subjects | Adolescent Adult Aged Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteria - isolation & purification Biological and medical sciences Ceftazidime Ceftazidime - administration & dosage Ceftazidime - therapeutic use Drug Therapy, Combination - therapeutic use Female Fever - drug therapy Humans Male Medical sciences Middle Aged Neutropenia Neutropenia - drug therapy Neutropenia - microbiology Pharmacology. Drug treatments Prospective Studies Random Allocation Research Article Superinfection - prevention & control Vancomycin Vancomycin - administration & dosage Vancomycin - therapeutic use |
| title | Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A40%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vancomycin%20is%20not%20an%20essential%20component%20of%20the%20initial%20empiric%20treatment%20regimen%20for%20febrile%20neutropenic%20patients%20receiving%20ceftazidime:%20a%20randomized%20prospective%20study&rft.jtitle=Antimicrobial%20Agents%20and%20Chemotherapy&rft.au=RAMPHAL,%20R&rft.date=1992-05-01&rft.volume=36&rft.issue=5&rft.spage=1062&rft.epage=1067&rft.pages=1062-1067&rft.issn=0066-4804&rft.eissn=1098-6596&rft.coden=AACHAX&rft_id=info:doi/10.1128/AAC.36.5.1062&rft_dat=%3Cproquest_pubme%3E73151138%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a471t-8a41d95cd4034be97cbe59b6f02ff58a36f49f248285da59ec394623bcc99ee33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73151138&rft_id=info:pmid/1510394&rfr_iscdi=true |